Bomedemstat

Bomedemstat (MK-3543, IMG-7289) is a small-molecule drug developed by Merck Sharp & Dohme. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06351631 (A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)), in myeloproliferative neoplasms. The largest, NCT06351631, plans to enrol 400 participants with primary completion expected 2034-12-04. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.